Enter multiple symbols separated by commas



  • Helping doctors share cancer research   Tuesday, 2 Jun 2015 | 1:18 PM ET
    Helping doctors share cancer research

    CNBC's Meg Tirrell provides insight to what Foundation Medicine, a cancer testing company, can do to better inform doctors on cancer via a database filled with research.

  • The FDA review highlights several safety issues with flibanserin, including low blood pressure and fainting spells. A panel of FDA experts will discuss the drug at a public meeting Thursday, before voting on whether to recommend its approval. Supporters of Sprout's drug say women's sexual disorders have been long overlooked by the FDA.

  • The big drivers in cancer therapy right now   Tuesday, 2 Jun 2015 | 5:45 AM ET
    The big drivers in cancer therapy right now

    Dan Mahony, fund manager at Polar Capital, discusses who are the main cancer drug players right now, as more treatments emerge.

  • How to pick a winning pharma stock   Tuesday, 2 Jun 2015 | 3:30 AM ET
    How to pick a winning pharma stock

    Jamie Davies, head of pharmaceuticals, healthcare and medical devices at BMI Research, says it's important to keep an eye on pharma companies that are de-diversifying and removing non-core assets.

  • CHICAGO, June 2- Drugmakers including Bristol-Myers Squibb Co and Merck& Co are testing which patients will most benefit from new cancer treatments based on a protein found in their tumors, but that guide, known as a biomarker, may be too unreliable, researchers and health experts said. Competitors Roche Holding, AstraZeneca and Pfizer also have similar drugs in...

  • Bristol's CEO optimistic of Opdivo's results Monday, 1 Jun 2015 | 5:46 PM ET
    Giovanni Caforio, CEO of Bristol-Myers Squibb.

    Despite disappointing trial results on Friday, the CEO of Bristol-Myers remains optimistic.

  • Puma Biotech selloff is an overreaction: Analyst Monday, 1 Jun 2015 | 5:44 PM ET

    RBC Capital Markets' Michael Yee said the selloff of Puma Biotech is in an overreaction and that the stock will represents an opportunity in the long run.

  • *Intel falls on $16.7 bln Altera buy. Boston Fed President Eric Rosengren said with little evidence of a rebound, the Fed is in no position to start raising interest rates for the first time since 2006.. But as the day has progessed, some of the enthusiasm has worn off since the debate continues as to when the Fed is going to raise rates, "said Bucky Hellwig, senior vice...

  • *Intel falls on Altera buy, weighs on Nasdaq, Dow and S&P. With little evidence of a rebound, the Fed is in no position to start raising interest rates for the first time since 2006, Boston Fed President Eric Rosengren said. "So far, economic data... does not suggest the Fed is going to raise rates in the near future, and the fact that the economy contracted in Q1 even with...

  • We deliver real value to patients: CLVS CEO   Monday, 1 Jun 2015 | 3:14 PM ET
    We deliver real value to patients: CLVS CEO

    Patrick Mahaffy, Clovis Oncology CEO, weighs in on drug prices, business development, and immunotherapy with CNBC's Meg Tirrell.

  • Puma Biotech is an opportunity: Pro   Monday, 1 Jun 2015 | 2:10 PM ET
    Puma Biotech is an opportunity: Pro

    Michael Yee, RBC Capital Markets biotech analyst, gives perspective to Puma Biotech and other action in the pharmaceutical industry.

  • *Intel falls on Altera buy, weighs on Nasdaq, Dow and S&P. *Microsoft jumps on report of German startup buy. "We're seeing a lot of counter trends in the market," said Rick Fier, director of trading at Conifer Securities in New York.

  • Airlines, tech & pharma earn spot in trades to go Monday, 1 Jun 2015 | 1:29 PM ET

    The "Halftime Report" traders give their trades for the second half.

  • Pfizer gaining market share in oncology: CEO Monday, 1 Jun 2015 | 1:09 PM ET
    Ian Read, CEO of Pfizer.

    Pfizer's share of the market for certain cancer drugs has increased from 10 to 20 percent, Chairman and CEO Ian Read tells CNBC.

  • Merck's fight against cancer   Monday, 1 Jun 2015 | 1:08 PM ET
    Merck's fight against cancer

    Merck's executive vice president Dr. Roger Perlmutter, discusses research on immunotherapy for certain colon cancers, and the players in the fight against cancer.

  • Pfizer CEO: Ibrance drug well received by physicians

    Pfizer CEO Ian Read, discusses the PALOMA-3 trial for its oncology treatment Ibrance to treat breast cancer, drug pricing and competition in the pharmaceutical industry.

  • A period of sustained growth: Bristol-Myers Squibb CEO

    Giovanni Caforio, Bristol-Myers Squibb CEO, joins CNBC's Meg Tirrell to discuss data in lung cancer and the importance of valuable medicines becoming available to patients.

  • ASCO targets immunotherapy and drug costs   Monday, 1 Jun 2015 | 9:16 AM ET
    ASCO targets immunotherapy and drug costs

    CNBC's Meg Tirrell has the update on the latest development from this year's American Society of Clinical Oncology meeting.

  • AstraZeneca CEO: Transforming cancer treatments   Monday, 1 Jun 2015 | 8:49 AM ET
    AstraZeneca CEO: Transforming cancer treatments

    CNBC's Meg Tirrell, and Pascal Soriot, AstraZeneca executive director & CEO, discuss the promising results in using immunotherapy to treat all kinds of cancers.

  • *Roche, AstraZeneca gain on positive updates. LONDON, June 1- European shares held steady at the start of the month on Monday, with a rally in some drug stocks on the back of positive company updates offset by lingering concerns over Greece's debt situation and weaker commodity stocks. Drugmakers Roche and AstraZeneca, up 2.2 percent and 1 percent respectively,...